You read that right…
I hate doctors. They drive me nuts…
You read that right…
I hate doctors. They drive me nuts…
He’s one of the most connected men on Wall Street I’ve ever met…
I first met him about 10 years ago at the Value Investing Congress. Ever since, I’ve enjoyed following his career. He’s made the cover of Kiplinger’s… was a regular on CNBC, Bloomberg TV, and Fox Business… and in 2000, he predicted the dot-com crash.
You’re flooding our inbox with questions…
So we’ll get straight into the topics that are on your mind.
I’m usually conservative when it comes to investing…
Some of the folks here at the office even tease me about it.
The cannabis industry is breaking new ground… and making investors a lot of money.
Each month, more and more U.S. states are legalizing cannabis for both recreational and medical purposes. After last year’s mid-term elections, Michigan became the 10th state to legalize recreational marijuana. And there are currently 33 states that have legalized medical marijuana.
We may be our own harshest critics. But we’re only tough on ourselves so we can be the best for you, our readers.
That’s why last week, when I shared our publisher’s Report Card results, I said:
I never pass up the opportunity to squeeze intel from people on the ground…
The bellhop seemed friendly as I walked into the lobby of the Mandarin Oriental Hotel in Shanghai. He spoke English well, and I asked him if he enjoyed working there.
Listen in to my chat this week with my friend Meb Faber.
Meb is the co-founder and chief investment officer of Cambria Investment Management… and a big deal in the finance world. He has an incredible Rolodex and an equally incredible guest list on his podcast.
After an Athenian jury sentenced him to death and his friends and followers in attendance began weeping, Socrates spoke…
“What is this strange outcry? … I have been told that a man should die in peace. Be quiet, then, and have patience.”
“Why can’t you guys just agree?”
It’s one of the most common questions I’ve seen recently. Folks don’t understand why all of the analysts here at Stansberry Research can’t agree on a specific topic…